Clinical EfficacyInterim data from ASCENT further underscores Yutrepia’s clinical benefits, showing a meaningful improvement in 6-minute walk distance, supporting evidence that higher treprostinil doses translate to better patient outcomes.
Market OpportunityThe PAH/PH-ILD market opportunity presents significant growth potential for Liquidia Technologies.
Regulatory ApprovalA transformative period is approaching for Liquidia Technologies due to the forthcoming PDUFA date for the approval of Yutrepia in PAH and PH-ILD.